PMC:7172841 / 33769-34052 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T231","span":{"begin":207,"end":217},"obj":"Body_part"},{"id":"T232","span":{"begin":218,"end":223},"obj":"Body_part"}],"attributes":[{"id":"A231","pred":"fma_id","subj":"T231","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A232","pred":"fma_id","subj":"T232","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T35","span":{"begin":218,"end":223},"obj":"Body_part"}],"attributes":[{"id":"A35","pred":"uberon_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T238","span":{"begin":188,"end":196},"obj":"Disease"}],"attributes":[{"id":"A238","pred":"mondo_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T309","span":{"begin":168,"end":173},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T310","span":{"begin":218,"end":223},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T311","span":{"begin":218,"end":223},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T282","span":{"begin":168,"end":173},"obj":"Chemical"}],"attributes":[{"id":"A282","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-sentences","denotations":[{"id":"T265","span":{"begin":0,"end":197},"obj":"Sentence"},{"id":"T266","span":{"begin":198,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T98","span":{"begin":18,"end":38},"obj":"Phenotype"}],"attributes":[{"id":"A98","pred":"hp_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T942","span":{"begin":18,"end":24},"obj":"UBERON:0002405"},{"id":"T943","span":{"begin":25,"end":38},"obj":"GO:0065007"},{"id":"T944","span":{"begin":99,"end":110},"obj":"DG_35"},{"id":"T945","span":{"begin":188,"end":196},"obj":"SP_7"},{"id":"T946","span":{"begin":207,"end":217},"obj":"CL:0000542"},{"id":"T947","span":{"begin":218,"end":223},"obj":"UBERON:0000178"},{"id":"T948","span":{"begin":262,"end":273},"obj":"DG_35"},{"id":"T31044","span":{"begin":18,"end":24},"obj":"UBERON:0002405;GO:0006955"},{"id":"T46550","span":{"begin":25,"end":38},"obj":"GO:0006955"},{"id":"T8807","span":{"begin":18,"end":24},"obj":"UBERON:0002405"},{"id":"T62677","span":{"begin":25,"end":38},"obj":"GO:0065007"},{"id":"T41838","span":{"begin":99,"end":110},"obj":"DG_35"},{"id":"T58306","span":{"begin":188,"end":196},"obj":"SP_7"},{"id":"T55151","span":{"begin":207,"end":217},"obj":"CL:0000542"},{"id":"T59630","span":{"begin":218,"end":223},"obj":"UBERON:0000178"},{"id":"T53589","span":{"begin":262,"end":273},"obj":"DG_35"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1198","span":{"begin":4,"end":12},"obj":"Species"},{"id":"1199","span":{"begin":99,"end":110},"obj":"Chemical"},{"id":"1200","span":{"begin":262,"end":273},"obj":"Chemical"},{"id":"1201","span":{"begin":188,"end":196},"obj":"Disease"}],"attributes":[{"id":"A1198","pred":"tao:has_database_id","subj":"1198","obj":"Tax:9606"},{"id":"A1199","pred":"tao:has_database_id","subj":"1199","obj":"MESH:C502936"},{"id":"A1200","pred":"tao:has_database_id","subj":"1200","obj":"MESH:C502936"},{"id":"A1201","pred":"tao:has_database_id","subj":"1201","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. Absolute lymphocyte blood counts were compared before and after Tocilizumab infusion."}